Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent In Vitro Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-01-03

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01312-10PMID 21199927PMCID PMC3067122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Artemisinin resistance: current status and scenarios for containment

  2010cited by this paper
• Artemisinin resistance: current status and scenarios for containment

  2010cited by this paper
• The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria

  2009cited by this paper
• Artemisinin-based combination therapy for treating uncomplicated malaria.

  2009cited by this paper
• A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter paper.

  2008cited by this paper
• Interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum in vitro

  2008influential reference
• A trial of combination antimalarial therapies in children from Papua New Guinea.

  2008cited by this paper
• Synergism between monodesbutyl-benflumetol and artemisinin in Plasmodium falciparum in vitro

  2008cited by this paper
• Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.

  2008cited by this paper
• Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria

  2007cited by this paper
• Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum

  2007influential reference
• Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer

  2006cited by this paper
• In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in Plasmodium vivax

  2006influential reference
• In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs

  2006cited by this paper
• Antimalarial drugs: QT prolongation and cardiac arrhythmias

  2005cited by this paper
• Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro

  2005cited by this paper
• Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

  2004cited by this paper
• Modified Fixed-Ratio Isobologram Method for Studying In Vitro Interactions between Atovaquone and Proguanil or Dihydroartemisinin against Drug-Resistant Strains of Plasmodium falciparum

  2004cited by this paper
• Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria

  2003cited by this paper
• Desbutyl-Benflumetol, a Novel Antimalarial Compound: In Vitro Activity in Fresh Isolates of Plasmodium falciparumfrom Thailand

  2001cited by this paper
• Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria

  2000cited by this paper
• Synergism of benflumetol and artemether in Plasmodium falciparum.

  1999cited by this paper
• The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects

  1998cited by this paper
• Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

  1998cited by this paper
• Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography.

  1996cited by this paper
• Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

  1995cited by this paper
• Eosinophil-rich, granulomatous inflammatory response to Plasmodium berghei hepatic schizonts in nonimmunized rats is age-related.

  1991cited by this paper
• The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro.

  1987cited by this paper
• Plasmodium falciparum: microaerophilic requirements in human red blood cells.

  1979cited by this paper
• A method for testing for synergy with any number of agents.

  1978influential reference
• Human malaria parasites in continuous culture.

  1976cited by this paper

• Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial

  2025cites this paper
• Combining the zebrafish embryo developmental toxicity assay (ZEDTA) with hemoglobin staining to accelerate the research of novel antimalarial drugs for pregnant women

  2025cites this paper
• Therapeutic efficacy of generic artemether–lumefantrine in the treatment of uncomplicated malaria in Ghana: assessing anti-malarial efficacy amidst pharmacogenetic variations

  2024influential citation
• A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria.

  2023cites this paper
• An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria

  2022cites this paper
• The effect of sickle cell genotype on the pharmacokinetic properties of artemether-lumefantrine in Tanzanian children

  2022cites this paper
• The pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal weight, overweight and obese healthy male adults.

  2021cites this paper
• Determination of antimalarial drugs in pharmaceutical formulations and human blood by liquid chromatography: a review.

  2021cites this paper
• Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations

  2021cites this paper
• The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria

  2021cites this paper
• Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania

  2020cites this paper
• Drug-drug Interactions between and Commonly-used Antiretroviral 2 Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.

  2020cites this paper
• The Role of Clinical Pharmacology in Chemotherapy of Multidrug‐Resistant Plasmodium falciparum

  2020cites this paper
• An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

  2020cites this paper
• Machine Learning Models Identify Inhibitors of SARS-CoV-2

  2020cites this paper
• Rapid and quantitative antimalarial drug efficacy testing via the magneto-optical detection of hemozoin

  2020cites this paper
• Pharmacogenomics in the Nigerian population: the past, the present and the future.

  2019cites this paper
• A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa

  2019cites this paper
• A randomised controlled trial of 3 versus 5 days artemether-lumefantrine regimen for 1 uncomplicated Plasmodium falciparum treatment in pregnancy in Africa

  2019cites this paper
• CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers

  2019cites this paper
• Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria

  2019cites this paper
• Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

  2019cites this paper
• Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics

  2018cites this paper
• BIOAVAILABILITY AND BIOEQUIVALENCE EVALUATION OF LOKMAL ® (ARTEMETHER-LUMEFANTRINE 80/480 MG FIXED DOSE TABLET): AN EMZOR ® PHARMACEUTICAL PRODUCT

  2018cites this paper
• Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling

  2017cites this paper
• The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome

  2017cites this paper
• High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series

  2017cites this paper
• Development and Validation of a GC-MS Method for the Quantitation of Nanoformulated Primaquine in Whole Blood and Plasma of Mouse Model

  2017cites this paper
• Effect of local food on lumefantrine bioavailability and population pharmacokinetics in Ugandan children with malaria

  2016influential citation
• To attach or not to attach : factors behind variable adhesion properties of cryopreserved human hepatocytes

  2016cites this paper
• The preparation of artemisinin-cholesterol conjugates as potential new drugs for treatment of intractable forms of tuberculosis and malaria

  2016cites this paper
• Degradation of Artemisinin-Based Combination Therapies under Tropical Conditions

  2016cites this paper
• Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children

  2016cites this paper
• Development and validation of a LC-MS/MS method for the quantitation of lumefantrine in mouse whole blood and plasma.

  2015cites this paper
• The treatment of malaria in Papua New Guinean children

  2015cites this paper
• Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study

  2015cites this paper
• Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data

  2015cites this paper
• Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy

  2015cites this paper
• A fast and sensitive method for quantifying lumefantrine and desbutyl-lumefantrine using LC-MS/MS.

  2015cites this paper
• In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.

  2015cites this paper
• Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria

  2015cites this paper
• Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border

  2015influential citation
• Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications

  2014cites this paper
• Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial

  2014cites this paper
• Pharmacological considerations in the design of anti-malarial drug combination therapies – is matching half-lives enough?

  2014cites this paper
• Population Pharmacokinetic-Pharmacodynamic Modelling of Antimalarial Treatment

  2014cites this paper
• Design and applications of bioprecursors: a retrometabolic approach.

  2014cites this paper
• Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda

  2013cites this paper
• DETEÇÃO DE HEMOZOÍNA EM ERITRÓCITOS INFETADOS COM PLASMODIUM FALCIPARUM POR CITOMETRIA DE FLUXO, PARA MONITORIZAÇÃO DO EFEITO DE ANTIMALÁRICOS

  2013cites this paper
• Investigation of the Functional Role of P-Glycoprotein in Limiting the Oral Bioavailability of Lumefantrine

  2013cites this paper
• Deteção de hemozoína em eritrócitos infetados com Plasmodium falciparum por citometria de fluxo, para monitorização do efeito de antimaláricos

  2013cites this paper
• Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy

  2013cites this paper
• Pharmacokinetics and pharmacodynamics of antimalarial drugs in pregnant women

  2013influential citation
• Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania

  2012cites this paper
• Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.

  2012cites this paper
• Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.

  2012cites this paper
• Investigation of the Plasmodium falciparum Food Vacuole through Inducible Expression of the Chloroquine Resistance Transporter (PfCRT)

  2012cites this paper
• In Vitro Antimalarial Activity and Drug Interactions of Fenofibric Acid

  2012cites this paper
• Investigation of volatile organic biomarkers derived from Plasmodium falciparum in vitro

  2012cites this paper
• Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.

  2012cites this paper
• Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats

  2011cites this paper
• The pharmacogenetics of antimalaria artemisinin combination therapy

  2011cites this paper
• Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.

  2011cites this paper
• Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria

  2011influential citation
• Population pharmacokinetics of artemether , lumefantrine and their 1 respective metabolites in Papua New Guinean children with uncomplicated 2 malaria 3 4

  2011influential citation
• Key Terms Matrix effect : Concomitant presence of other substances in the ion source affects ionization of the analyte leading to enhanced or suppressed signal of the analyte

  2010cites this paper